相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
Michele Cavo et al.
LANCET HAEMATOLOGY (2020)
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Thierry Facon et al.
BLOOD (2018)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial
Sarah A. Holstein et al.
LANCET HAEMATOLOGY (2017)
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial
Francesca Gay et al.
LANCET ONCOLOGY (2015)
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data
Antonio Palumbo et al.
LANCET ONCOLOGY (2014)
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
A. Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma
Neil C. Dunavin et al.
LEUKEMIA & LYMPHOMA (2013)
Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma
Shaji K. Kumar et al.
CANCER (2012)
Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar et al.
BLOOD (2011)
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Paul G. Richardson et al.
BLOOD (2010)
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2010)
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
M. A. Dimopoulos et al.
LEUKEMIA (2009)
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma:: A report from the GIMEMA -: Italian multiple myeloma network
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma
Martha Q. Lacy et al.
MAYO CLINIC PROCEEDINGS (2007)
High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials
John Koreth et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321
B Barlogie et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the group myelome-autogreffe
J Fermand et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
SV Rajkumar et al.
BLOOD (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment
A Trotti et al.
SEMINARS IN RADIATION ONCOLOGY (2003)
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
JA Child et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission.: Results of a non-randomized study from a single institution
J Bladé et al.
BONE MARROW TRANSPLANTATION (2000)
分享论文
